Dif­ferential Dia­gnosis of Tauopathies –  a Clinical Approach


Authors: R. Rusina 1,2;  R. Matěj 3,4;  E. Růžička 1;  J. Roth 1
Authors‘ workplace: Neurologická klinika a Centrum klinických neurověd, 1. LF UK a VFN v Praze 1;  Neurologické oddělení, Thomayerova nemocnice, Praha 2;  Oddělení patologie a molekulární medicíny, Thomayerova nemocnice, Praha 3;  Ústav patologie, 3. LF UK v Praze 4
Published in: Cesk Slov Neurol N 2015; 78/111(5): 526-534
Category: Review Article
doi: 10.14735/amcsnn2015526

Overview

Tauopathies are neurodegenerative disorders characterized by accumulation of abnormally modified forms of the tau-protein, predominantly in frontal, temporal and parietal cortical regions, basal ganglia and in the midbrain. Tauopathies are well defined from the molecular biological and biochemical point of view; clinical symptoms may be, however, heterogeneous. Common signs of frontotemporal lobar degenerations include a more or less prominent syndrome of frontotemporal dementia. On the other hand, the clinical picture of frontotemporal dementia may not be caused by a tauopathy only; in many cases the underlying etiopathogenic cause is different. The aim of our review is to classify the relationship between tauopathies and frontotemporal lobar degenerations. This review contains a proposal of a practical approach to refining clinical diagnosis of the different tauopathies.

Key words:
neurodegeneration – tauopathy – frontotemporal lobar degeneration –progressive supranuclear palsy – progressive aphasia – corticobasal syndrome

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manu­script met the ICMJE “uniform requirements” for biomedical papers.


Sources

1. Spil­lantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol 2013; 12(6): 609– 622. doi: 10.1016/ S1474‑ 4422(13)70090‑ 5.

2. Peden AH, Ironside JW. Molecular pathology in neurodegenerative diseases. Cur­r Drug Targets 2012; 13(12): 1548– 1559.

3. Wil­liams DR. Tauopathies: clas­sification and clinical update on neurodegenerative diseases as­sociated with microtubule‑as­sociated protein tau. Intern Med J 2006; 36(10): 652– 660.

4. Wil­liams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ et al. Pathological tau burden and distribution distinguishes progres­sive supranuclear palsy‑ parkinsonism from Richardson‘s syndrome. Brain 2007; 130(6): 1566– 1576.

5. Rademakers R, Neuman­n M, Mackenzie IR. Advances in understand­ing the molecular basis of frontotemporal dementia. Nat Rev Neurol 2012; 8(8): 423– 434. doi: 10.1038/ nrneurol.2012.117.

6. Rohan Z, Matej R. Cur­rent concepts in the clas­sification and dia­gnosis of frontotemporal lobar degenerations: a practical approach. Arch Pathol Lab Med 2014; 138(1): 132– 138. doi: 10.5858/ arpa.2012‑ 0510‑ RS.

7. Gros­sman M. The non‑fluent/ agram­matic variant of primary progres­sive aphasia. Lancet Neurol 2012; 11(6): 545– 555. doi: 10.1016/ S1474‑ 4422(12)70099‑ 6.

8. Dickson DW, Rademakers R, Hutton ML. Progres­sive supranuclear palsy: pathology and genetics. Brain Pathol 2007; 17(1): 74– 82.

9. Mathew R, Bak TH, Hodges JR. Dia­gnostic criteria for corticobasal syndrome: a comparative study. J Neurol Neurosurg Psychiatry 2012; 83(4): 405– 410. doi: 10.1136/ jn­np‑ 2011‑ 300875.

10. Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF,Abner EL, Alafuzof­f I et al. Primary age‑related tauopathy (PART): a com­mon pathology as­sociated with human aging. Acta Neuropathol 2014; 128(6): 755– 766. doi: 10.1007/ s00401‑ 014‑ 1349‑ 0.

11. Josephs KA, Petersen RC, Knopman DS, Boeve BF, Whitwel­l JL, Duf­fy JR et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006; 66(1): 41– 48.

12. Litvan I, MacIntyre A, Goetz CG, Wen­n­ing GK, Jel­linger K, Verny M et al. Accuracy of the clinical dia­gnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 1998; 55(7): 969– 978.

13. Onyike CU, Diehl‑ Schmid J. The epidemiology of frontotemporal dementia. Int Rev Psychiatry 2013; 25(2): 130– 137. doi: 10.3109/ 09540261.2013.776523.

14. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J et al. Sensitivity of revised diag­nostic criteria for the behavioral variant of frontotemporal dementia. Brain 2011; 134(9): 2456– 2477. doi: 10.1093/ brain/ awr179.

15. Gorno‑ Tempini ML, Hil­lis AE, Weintraub S, Kertesz A,Mendez M, Cappa SF et al. Clas­sification of primary progres­sive aphasia and its variants. Neurology 2011; 76(11): 1006– 1014. doi: 10.1212/ WNL.0b013e31821103e6.

16. Josephs KA, Duf­fy JR, Strand EA, Machulda M­M, Senjem ML, Master AV et al. Characteriz­ing a neurodegenerative syndrome: primary progres­sive apraxia of speech. Brain 2012; 135(5): 1522– 1536. doi: 10.1093/ brain// aws032.

17. Wadia PM, Lang AE. The many faces of corticobasal degeneration. Parkinsonism Relat Disord 2007; 13 (Suppl 3): S336– S340. doi: 10.1016/ S1353‑ 8020(08)70027‑ 0.

18. Has­san A, Whitwel­l JL, Josephs KA. The corticobasal syndrome – Alzheimer‘s disease conundrum Expert Rev Neurother 2011; 11(11): 1569– 1578. doi: 10.1586/ ern.11.153.

19. Johanidesová S, Rusina R, Houška P, Kel­ler J, Matěj R.Alzheimerova nemoc probíhající pod obrazem kortikobazální degenerace –  kazuistika. Cesk Slov Neurol N 2012; 75/ 108(3): 373– 377.

20. L­ing H, O’Sul­livan SS, Holton JL, Revesz T, Mas­sey LA, Wil­liams DR et al. Does corticobasal degeneration exist? A clinicopathological re‑evaluation. Brain 2010; 133(7): 2045– 2057. doi: 10.1093/ brain/ awq123.

21. Steele JC, Richardson JC, Olszewski J. Progres­sive supranuclear palsy. A heterogeneous degeneration involv­ing the brain stem, basal ganglia and cerebel­lum with vertical supranuclear gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10: 333– 359.

22. Liscic RM, Srulijes K, Gröger A, Maetzler W, Berg D. Dif­ferentiation of progres­sive supranuclear palsy: clinical, imag­ing and laboratory tools. Acta Neurol Scand 2013; 127(5): 362– 370. doi: 10.1111/ ane.12067.

23. Menšíková K, Kaňovský P, Kaiserová M, Nestrašil I, Bareš M. Proměnlivá tvář parkinsonské neurodegenerace. Cesk Slov Neurol N 2013; 76/ 109(1): 26– 34.

24. Respondek G, Roeber S, Kretzschmar H, Troakes C, Al‑ Sar­raj S, Gelpi E et al. Accuracy of the National Institute for Neurological Disorders and Stroke/ Society for Progres­sive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the dia­gnosis of progres­sive supranuclear palsy. Mov Disord 2013; 28(4): 504– 509. doi: 10.1002/ mds.25327.

25. Richardson JC, Steele J, Olszewski J. Supranuclear ophthalmoplegia, pseudobulbar palsy, nuchal dystonia and dementia. A clinical report on eight cases of „heterogenous system degeneration“. Trans Am Neurol As­soc 1963; 88: 25– 29.

26. Wil­liams DR, de Silva R, Paviour DC, Pittman A, Watt HC,Kilford L et al. Characteristics of two distinct clinical phenotypes in pathological­ly proven progres­sive supranuclear palsy: Richardson‘s syndrome and PSP‑ parkinsonism. Brain 2005; 128(6): 1247– 1258.

27. Imai H, Nakamura T, Kondo T, Narabayashi H. Dopa‑ unresponsive pure akinesia or freezing. A condition within a wide spectrum of PSP? Adv Neurol 1993; 60: 622– 625.

28. Wil­liams DR, Holton JL, Strand K, Revesz T, Lees AJ. Pure akinesia with gait freezing: a third clinical phenotype of progres­sive supranuclear palsy. Mov Disord 2007; 22(15): 2235– 2241.

29. Josephs KA, Boeve BF, Duf­fy JR, Smith GE, Knopman DS,Parisi JE et al. Atypical progres­sive supranuclear palsy underly­ing progres­sive apraxia of speech and nonfluent aphasia. Neurocase 2005; 11(4): 283– 296.

30. Thal DR, Schultz C, Botez G, Del Tredici K, Mrak RE, Grif­fin WS et al. The impact of argyrophilic grain disease on the development of dementia and its relationship to concur­rent Alzheimer‘s disease‑related pathology. Neuropathol Appl Neurobio­l 2005; 31(3): 270– 279.

31. Matěj R, Koukolík F. Nemoc s argyrofilními zrny: kazuistické sdělení prvních dvou případů dia­gnostikovaných v ČR a přehled literatury. Cesk Patol 2006; 42(2): 66– 70.

32. Rosen HJ, Gorno‑ Tempini ML, Goldman W, Per­ry RJ, Schuf­f N, Weiner M et al. Pattern of brain atrophy in frontotemporal dementia and semantic dementia. Neurology 2002; 58(2): 198– 208.

33. Rusz J, Bon­net C, Klempíř J, Tykalová T, Baborová E,Novotný M et al. Speech disorders reflect dif­fer­ing pathophysiology in Parkinson’s disease, progres­sive supranuclear palsy and multiple system atrophy. J Neurol 2015; 262(4): 992– 1001. doi: 10.1007/ s00415‑ 015‑ 7671‑ 1.

34. Dugger BN, Adler CH, Shil­l HA, Cavines­s J, Jacobson S, Driver‑ Dunckley E et al. Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism Relat Disord 2014; 20(5): 525– 529. doi: 10.1016/ j.parkreldis.2014.02.012.

35. Rusina R, Pazdera L, Kulišťák P, Vyšata O, Matěj R. Pick and Alzheimer diseases: a rare comorbidity present­ing as corticobasal syndrome. Cogn Behav Neurol 2013; 26(4): 189– 194. doi: 10.1097/ WN­n.0000000000000011.

36. Menšíková K, Matěj R, Tučková L, Rusina R, Ehrman­n J, Kaňovský P. Progres­sive supranuclear palsy phenotype mimick­ing synucleinopathies. J Neurol Sci 2013; 329(1– 2): 34– 37. doi: 10.1016/ j.jns.2013.03.008.

37. Litvan I, Agid Y, Calne D, Campbel­l G, Dubois B, Duvoisin RC et al. Clinical research criteria for the dia­g­nosis of progres­sive supranuclear palsy (Steele‑ Richardson‑ Olszewski syndrome): report of the NINDS‑ SPSP international workshop. Neurology 1996; 47(1): 1– 9.

Labels
Paediatric neurology Neurosurgery Neurology

Article was published in

Czech and Slovak Neurology and Neurosurgery

Issue 5

2015 Issue 5

Most read in this issue
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account